Sumatriptan-naproxen Fixed Combination for Acute Treatment of Migraine: a Critical Appraisal

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2010 Apr 7

PMID 20368903

Citations 11

Authors

Chaouki K Khoury

James R Couch

Affiliations

Soon will be listed here.

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen and naproxen sodium, are effective yet nonspecific analgesic and anti-inflammatory drugs, which work for a variety of pain and inflammatory syndromes, including migraine. In migraine, their analgesic effect helps relieve the headache, while their anti-inflammatory effect decreases the neurogenic inflammation in the trigeminal ganglion. This is the hypothesized mechanism by which they prevent the development of central sensitization. Triptans, including sumatriptan, work early in the migraine process at the trigeminovascular unit as agonists of the serotonin receptors (5-HT receptors) 1B and 1D. They block vasoconstriction and block transmission of signals to the trigeminal nucleus and thus prevent peripheral sensitization. Therefore, combining these two drugs is an attractive modality for the abortive treatment of migraine. Sumatriptan-naproxen fixed combination tablet (Treximet [sumatriptan-naproxen]) proves to be an effective and well tolerated drug that combines these two mechanisms; yet is far from being the ultimate in migraine abortive therapy, and further research remains essential.

Citing Articles

Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.

Rommasi F, Nasiri M, Mirsaeidi M Mol Cell Biochem. 2022; 477(3):711-726.

PMID: 35013850 PMC: 8747854. DOI: 10.1007/s11010-021-04325-9.

Voltammetric detection of sumatriptan in the presence of naproxen using FeO@ZIF-8 nanoparticles modified screen printed graphite electrode.

Tajik S, Shahsavari M, Sheikhshoaie I, Garkani Nejad F, Beitollahi H Sci Rep. 2021; 11(1):24068.

PMID: 34912041 PMC: 8674320. DOI: 10.1038/s41598-021-98598-1.

The fifth cranial nerve in headaches.

Edvinsson J, Vigano A, Alekseeva A, Alieva E, Arruda R, De Luca C J Headache Pain. 2020; 21(1):65.

PMID: 32503421 PMC: 7275328. DOI: 10.1186/s10194-020-01134-1.

Liposomal Curcumin Enhances the Effect of Naproxen in a Rat Model of Migraine.

Bulboaca A, Bolboaca S, Bulboaca A, Porfire A, Tefas L, Suciu S Med Sci Monit. 2019; 25:5087-5097.

PMID: 31287810 PMC: 6636407. DOI: 10.12659/MSM.915607.

Modulation of brain networks by sumatriptan-naproxen in the inflammatory soup migraine model.

Bishop J, Becerra L, Barmettler G, Chang P, Kainz V, Burstein R Pain. 2019; 160(9):2161-2171.

PMID: 31033778 PMC: 7193782. DOI: 10.1097/j.pain.0000000000001583.

References

Evers S, Afra J, Frese A, Goadsby P, Linde M, May A . EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009; 16(9):968-81. DOI: 10.1111/j.1468-1331.2009.02748.x. View

Silberstein S, Mannix L, Goldstein J, Couch J, Byrd S, Ames M . Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008; 71(2):114-21. DOI: 10.1212/01.wnl.0000316800.22949.20. View

Hsu V . Sumatriptan: a new drug for vascular headache. Clin Pharm. 1992; 11(11):919-29. View

Rasmussen B . Epidemiology of headache. Cephalalgia. 2001; 21(7):774-7. DOI: 10.1177/033310240102100708. View

Burstein R, Jakubowski M . Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004; 55(1):27-36. DOI: 10.1002/ana.10785. View

Johnson E, Ratcliffe D, WILKINSON M . Naproxen sodium in the treatment of migraine. Cephalalgia. 1985; 5(1):5-10. DOI: 10.1046/j.1468-2982.1985.0501005.x. View

DIXON C, Park G, Tarbit M . Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol. 1994; 47(7):1253-7. DOI: 10.1016/0006-2952(94)90397-2. View

Russell M, Rishoj Nielsen M, Cleal A, Pilgrim A, Olesen J . A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia. 1994; 14(4):291-6. DOI: 10.1046/j.1468-2982.1994.1404291.x. View

Kurumbail R, Stevens A, Gierse J, McDonald J, Stegeman R, Pak J . Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384(6610):644-8. DOI: 10.1038/384644a0. View

10.

Burstein R, Collins B, Jakubowski M . Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004; 55(1):19-26. DOI: 10.1002/ana.10786. View

11.

Rapoport A . Acute treatment of headache. J Headache Pain. 2006; 7(5):355-9. PMC: 3468178. DOI: 10.1007/s10194-006-0327-x. View

12.

DIXON C, Saynor D, Andrew P, Oxford J, Bradbury A, Tarbit M . Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos. 1993; 21(5):761-9. View

13.

Fox A, Spierings E . Sumatriptan and pregnancy outcome. Headache. 2001; 40(10):860-1. DOI: 10.1046/j.1526-4610.2000.00158.x. View

14.

Makela A . Naproxen in the treatment of juvenile rheumatoid arthritis. Metabolism, safety and efficacy. Scand J Rheumatol. 1977; 6(4):193-205. DOI: 10.3109/03009747709095449. View

15.

Schwartz B, Stewart W, Simon D, Lipton R . Epidemiology of tension-type headache. JAMA. 1998; 279(5):381-3. DOI: 10.1001/jama.279.5.381. View

16.

Harriott A, Gold M . Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues. Cephalalgia. 2008; 28(9):933-44. PMC: 2682350. DOI: 10.1111/j.1468-2982.2008.01635.x. View

17.

Cryer B, Dubois A . The advent of highly selective inhibitors of cyclooxygenase--a review. Prostaglandins Other Lipid Mediat. 1999; 56(5-6):341-61. DOI: 10.1016/s0090-6980(98)00064-1. View

18.

Fullerton T, Gengo F . Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother. 1992; 26(6):800-8. DOI: 10.1177/106002809202600611. View

19.

. Sumatriptan: a new approach to migraine. Drug Ther Bull. 1992; 30(22):85-7. View

20.

Osterhaus J, Gutterman D, Plachetka J . Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992; 2(1):67-76. DOI: 10.2165/00019053-199202010-00008. View